Jounce rings out the old year with a $75M IPO bid for the New Year

Five months af­ter Cel­gene part­nered with Jounce Ther­a­peu­tics on a $2.56 bil­lion de­vel­op­ment deal, the Cam­bridge, MA-based biotech is end­ing the year with a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.